Ranitidine bismuth citrate

Show results for

Unknown (2)
Proteomics (1)
Genomics (1)

Organisms

Alphavirus (1)
Anemia (1)
Archaea (1)
Bacteria (1)
Betaherpesvirinae (1)
Borrelia (1)
Chlamydomonas reinhardtii (1)
Chlorella vulgaris (1)
Clostridium perfringens (1)
Dengue virus (1)
Eukaryota (1)
Hepatitis B virus (1)
Human alphaherpesvirus 1 (1)
Human betaherpesvirus 5 (1)
Influenza A virus (1)
Influenza C virus (1)
Japanese encephalitis virus group (1)
Kamptonema sp. (1)
Listeria monocytogenes (1)
Mammarenavirus (1)
Miscanthus x giganteus (1)
Mycobacterium tuberculosis (1)
Orthoflavivirus (1)
Pseudomonas aeruginosa (1)
Rattus (1)
Sarbecovirus (1)
Severe acute respiratory syndrome coronavirus 2 (1)
Staphylococcus aureus (1)
Streptococcus pneumoniae (1)
Viruses (1)

Repository

pride (1)
ENA (1)

Technology Type

Mass Spectrometry (1)
Shotgun proteomics (1)

Publication Date

2024 (1)

Release Date

2021 (1)
2010 (1)

Lab affiliation

1Discipline of Periodontology, Faculty of Dentistry, The University of Hong Kong (1)

First Public Date

2019 (1)

Previous page
1 / 1
You're on page 1
Next page

Sort by:

Relevance

Page size

LC MS/MS comparative proteomic analysis of Porphyromonas gingivalis treated with ranitidine bismuth citrate

Label-free quantification of quantitative proteomics was performed to to extensively understand the effects of bismuth drugs (25 µM RBC) on Porphyromonas gingivalis.

ORGANISM(S): Porphyromonas gingivalis ATCC 33277

2024-10-23 | PXD008869 | Pride

RNA-seq of Porphyromonas gingivalis treated with ranitidine bismuth citrate

PRJNA433060 | ENA

Polymeric architectures of bismuth citrate based on dimeric building blocks.

Not available

S-EPMC7088795 | biostudies-literature

Inhibition of Aspirin-Induced Gastrointestinal Injury: Systematic Review and Network Meta-Analysis.